Wavegate Corporation Raises $26M in Series A Funding

Wavegate Corporation, a Lake Charles, LA-based developer of neuromodulation technology for chronic pain management, raised $26M in Series A funding.

The round was led by UCEA Capital Partners.

The company intends to use the funds to accelerate the development of its proprietary Ellipse^™ platform, featuring StimuLux^™ technology, designed to provide therapeutic solutions for chronic pain patients.

Led by CEO Dr. Erich Wolf, Wavegate provides the Ellipse^™ spinal cord stimulator that uses optical reflectometry to offer a closed-loop adaptive modulation, uniquely adjusting stimulation in real-time based on spinal cord movement. This technology, which received FDA Breakthrough Device designation, aims tp improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation.

FinSMEs

11/12/2024